Gennao Bio

Gennao Bio is developing first-in-class, targeted nucleic acid therapeutics utilizing its proprietary, non-viral GMAB platform technology. We are developing this delivery system with an initial focus in oncology and rare monogenic skeletal muscle diseases. Goswami joins the Gennao team with over 20 years of experience in private practice at Ballard Spahr LLP in Philadelphia. At Gennao Bio, we are driven by a passion to transform genetic medicine and believe we have the technology to accomplish this. We are a dedicated team of innovators working with a sense of urgency to bring first-in-class treatments to patients. GMAB is an adaptive technology that uses a novel cell-penetrating antibody to specifically deliver nucleic acid payloads to select cells while distinctly avoiding the endocytic pathway. Our cell-penetrating antibody can bind to and deliver a broad range of nucleic acid payloads including single-stranded/double-stranded RNA, mRNA, synthetic RNA, DNA, RNAi and ASOs. Additionally, GMAB complexes have demonstrated the ability to be delivered into both the cytoplasm and the nucleus.